We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men-United States, 2012-2014.
- Authors
Meites, Elissa; Gorbach, Pamina M.; Gratzer, Beau; Panicker, Gitika; Steinau, Martin; Collins, Tom; Parrish, Adam; Randel, Cody; McGrath, Mark; Carrasco, Steven; Moore, Janell; Zaidi, Akbar; Braxton, Jim; Kerndt, Peter R.; Unger, Elizabeth R.; Crosby, Richard A.; Markowitz, Lauri E.
- Abstract
<bold>Background: </bold>Gay, bisexual, and other men who have sex with men (MSM) are at high risk for human papillomavirus (HPV) infection; vaccination is recommended for US males, including MSM through age 26 years. We assessed evidence of HPV among vaccine-eligible MSM and transgender women to monitor vaccine impact.<bold>Methods: </bold>During 2012-2014, MSM aged 18-26 years at select clinics completed a computer-assisted self-interview regarding sexual behavior, human immunodeficiency virus (HIV) status, and vaccinations. Self-collected anal swab and oral rinse specimens were tested for HPV DNA (37 types) by L1 consensus polymerase chain reaction; serum was tested for HPV antibodies (4 types) by a multiplexed virus-like particle-based immunoglobulin G direct enzyme-linked immunosorbent assay.<bold>Results: </bold>Among 922 vaccine-eligible participants, the mean age was 23 years, and the mean number of lifetime sex partners was 37. Among 834 without HIV infection, any anal HPV was detected in 69.4% and any oral HPV in 8.4%, yet only 8.5% had evidence of exposure to all quadrivalent vaccine types. In multivariate analysis, HPV prevalence varied significantly (P < .05) by HIV status, sexual orientation, and lifetime number of sex partners, but not by race/ethnicity.<bold>Discussions: </bold>Most young MSM lacked evidence of current or past infection with all vaccine-type HPV types, suggesting that they could benefit from vaccination. The impact of vaccination among MSM may be assessed by monitoring HPV prevalence, including in self-collected specimens.
- Subjects
HUMAN papillomavirus vaccines; HIV; POLYMERASE chain reaction; DISEASE prevalence; ENZYME-linked immunosorbent assay
- Publication
Journal of Infectious Diseases, 2016, Vol 214, Issue 5, p689
- ISSN
0022-1899
- Publication type
journal article
- DOI
10.1093/infdis/jiw232